MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Amryt Pharma plc Operating Expenses 2011-2026 | AMYT
Annual Operating Expenses Amryt Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 109 M | 52.2 M | 27.9 M | 25.9 M | 6.95 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 6.95 M | 44.4 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
106 M | $ 4.73 | 0.42 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.4 | 4.29 % | $ 342 M |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 333.39 | -1.77 % | $ 43.7 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.17 | 3.93 % | $ 5.22 M |  Israel |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.73 | 3.04 % | $ 8.97 B |  Australia |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 2.17 | 5.85 % | $ 451 M | USA |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 7.42 | -15.1 % | $ 73.3 M | USA |
|
Forte Biosciences
FBRX
|
70.7 M | $ 31.28 | -3.52 % | $ 405 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
709 M | $ 29.16 | 0.97 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
67.9 M | $ 29.3 | 0.83 % | $ 18.8 B |  Danmark |
 |
GT Biopharma
GTBP
|
21.3 M | $ 0.39 | -0.26 % | $ 2.15 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.68 | 1.4 % | $ 1.01 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 29.22 | -0.24 % | $ 1.68 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 99.47 | 1.08 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 7.6 | -1.68 % | $ 68.6 M | USA |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 1.21 | 6.14 % | $ 152 M | Germany |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.55 | -0.64 % | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Incyte Corporation
INCY
|
1.62 B | $ 97.1 | -0.6 % | $ 19 B | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.24 | 2.17 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 24.58 | -2.03 % | $ 3.13 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.69 | 3.68 % | $ 235 M | France |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.49 | 0.68 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |